Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1045P is classified as a **pseudogene** of the U6 small nuclear RNA family. U6 small nuclear RNAs (snRNAs) are integral parts of the spliceosome and are essential for pre-mRNA splicing in eukaryotic cells, acting as non-coding RNA components of the spliceosomal machinery[1][2]. However, a pseudogene like RNU6-1045P, by definition, lacks protein-coding potential and does not produce a functional RNA product involved in the spliceosome. Typically, pseudogenes arise from gene duplication or retrotransposition and have lost their original function due to mutations or truncation. There is no evidence supporting a molecular function or a role in disease, nor is RNU6-1045P considered a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 1045, pseudogene (RNU6-1045P).